Spruce Biosciences (SPRB) Preferred Stock Liabilities (2019 - 2020)
Spruce Biosciences (SPRB) posted quarterly Preferred Stock Liabilities of $115.4 million for Q3 2020, up 315.08% year-over-year from $27.8 million in Q4 2019, and up 164.49% quarter-over-quarter from $43.6 million in Q2 2020.
Spruce Biosciences (SPRB) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Spruce Biosciences (SPRB) has reported Preferred Stock Liabilities for 2 consecutive years, with $115.4 million the latest figure, recorded in Q3 2020.
- In Q3 2020, Preferred Stock Liabilities rose 315.08% year-over-year to $115.4 million; the TTM figure through Sep 2020 stood at $115.4 million (up 315.08% YoY), while the FY2019 annual figure was $27.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $115.4 million in Q3 2020 per SPRB's latest filing, from $43.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $115.4 million in Q3 2020 and bottomed at $27.8 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 115.45 Mn |
| Jun 30, 2020 | 43.65 Mn |
| Mar 31, 2020 | 43.65 Mn |
| Dec 31, 2019 | 27.81 Mn |
| Sep 30, 2019 | 27.81 Mn |